M1 Kliniken AG Reports Strong Financial Performance with 11% EBIT Growth in First Nine Months of 2025
TL;DR
M1 Kliniken AG's strategic sale of HAEMATO Pharm and focus on medical aesthetics positions investors for advantage with 11% EBIT growth and expanding market leadership.
M1 Kliniken achieved profitability through efficiency measures, capacity expansion, and optimized processes, resulting in 6.7% revenue growth and improved EBIT margins across segments.
M1 Kliniken's expansion of medical aesthetic services provides accessible, physician-performed treatments at leading prices, improving patient access to quality care globally.
M1 Kliniken operates 58 clinics across ten countries and aims to become the world's leading aesthetic medicine brand by 2029 through strategic vertical integration.
Found this article helpful?
Share it with your network and spread the knowledge!
M1 Kliniken AG successfully closed the last nine months of 2025, continuing its profitable growth trajectory with consistent implementation of efficiency measures and targeted expansion of medical capacities contributing significantly to improved profits. The company reported group revenue growth of 6.7% to EUR 274.3 million compared to EUR 257.2 million in the same period last year, while EBITDA increased by 9% to EUR 28.2 million from EUR 25.9 million in the previous year.
The company achieved an 11% increase in EBIT to EUR 24.5 million, up from EUR 22.1 million in the first nine months of 2024, with the EBIT margin improving to 8.9% from 8.6%. Earnings before tax rose by 10% to EUR 24.4 million, and earnings per share reached EUR 0.86 compared to EUR 0.77 in the prior year period. This financial performance underscores the company's ability to maintain profitability while expanding operations, making it an important indicator for investors in the healthcare and medical aesthetics sector.
The Beauty segment emerged as the key growth driver, with revenue increasing by 9.5% to EUR 77.8 million and EBIT surging by 29.7% to EUR 21.1 million. The segment's EBIT margin improved significantly to 27.1% from 22.9% in the previous year, demonstrating the effectiveness of efficiency gains through optimized processes and higher utilization of medical capacities. The company's targeted pricing strategy aimed at attracting new customer groups has supported market share expansion without compromising margin quality, positioning M1 as the leading provider of high-quality aesthetic medicine at competitive prices.
Meanwhile, the Trading segment recorded solid revenue growth of 6% to EUR 196.5 million, though EBIT declined by 41.4% to EUR 3.4 million compared to the previous year's EUR 5.8 million. The company announced that its 85% subsidiary, HAEMATO AG, has signed an agreement to sell its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe's leading healthcare providers based in Mannheim. This transaction, subject to usual antitrust approvals, represents a strategic move to position M1 Kliniken AG as the world's leading vertically integrated pure-play provider of medical aesthetics.
Looking forward, M1 Kliniken AG plans to continue its profitable growth trajectory by expanding its network of national and international clinics. The company aims to increase its figure to between EUR 200 million and EUR 300 million by 2029 while maintaining a sustainable EBIT margin of at least 20%. The Group is consistently pursuing the goal of establishing M1 Med Beauty as the world's leading brand for aesthetic medicine, with current operations spanning 58 clinics in ten countries under the M1 Med Beauty brand. Additional information about the company's performance and strategy can be found at https://www.newmediawire.com.
Curated from NewMediaWire
